An exploratory double-blind, randomized, placebo-controlled study to assess the efficacy of CitruSlim on body composition and lipid parameters in obese individuals
| Autor: | Shalini Srivastava, Pablo Alarcón, Rafael A. Burgos, Dante Cáceres, Juan L. Hancke |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
medicine.medical_specialty biology business.industry Placebo-controlled study medicine.disease Placebo biology.organism_classification Obesity Lipids Body Mass Index Clinical trial Tolerability Double-Blind Method Internal medicine Weight Loss medicine Body Composition Humans Eurycoma longifolia Anti-Obesity Agents business Body mass index Dyslipidemia |
| Zdroj: | Phytotherapy research : PTRREFERENCES. 35(12) |
| ISSN: | 1099-1573 |
| Popis: | The prevalence of obesity in developing and developed countries has been well recognized, and the worldwide obesity rates have nearly tripled since 1975, according to the World Health Organization. CitruSlim, a standardized product containing a blend of Citrus bergamia and Eurycoma longifolia, can reduce cortisol, cholesterol, triglycerides, and hyperglycemia. These properties can contribute to reduction in body weight or body mass index (BMI) in obese patients. A randomized, double-blind, placebo-controlled clinical study was designed to evaluate the efficacy and tolerability of CitruSlim in body weight management in obese individuals, and the results were compared with that of placebo. A total of 97 participants were allocated, randomized, and treated with CitruSlim high-dose (HD, 400 mg), CitruSlim low-dose (LD, 200 mg), and placebo for 112 days. At the end of the study, CitruSlim HD and CitruSlim LD significantly reduced BMI compared to the placebo group and were well tolerated; however, it did not improve parameters associated with dyslipidemia and metabolic disturbances. The study findings suggested that CitruSlim was effective in reducing body weight in obese patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text